AlloMap molecular expression testing: Difference between revisions

Revision as of 03:42, 20 May 2012

Revision as of 19:57, 20 May 2012

Line 17:

=== IMAGE Study ===

A comparative effectiveness study, the Invasive Monitoring Attenuation through Gene Expression (IMAGE) Study, compared clinical outcomes of patients managed with AlloMap to outcomes of patients managed with endomyocardial biopsy. The study, which ran from 2005–09, included 602 patients from thirteen U.S. centers who were at least six months post-transplant. The results showed that AlloMap was not inferior to endomyocardial biopsy with respect to clinical outcomes when used to monitor stable, asymptomatic heart transplant patients.<ref>{{cite journal |last1=Pham |first1=MX |last2=Teuteberg |first2=JJ |last3=Kfoury |first3=AG |last4=Starling |first4=RC |last5=Deng |first5=MC |last6=Cappola |first6=TP |last7=Kao |first7=A |last8=Anderson |first8=AS |last9=Cotts |first9=WG |title=Gene-expression profiling for rejection surveillance after cardiac transplantation |journal=The New England journalJournal of medicineMedicine |volume=362 |issue=20 |pages=1890–900 |year=2010 |pmid=20413602 |doi=10.1056/NEJMoa0912965}}</ref>

== Indications for use ==